Home The History of Synthetic Biology Designing Synthetic Biotics Pipeline Our People Leadership Board of Directors Founders and Advisors Investors + Media Company Overview News News Releases In the News Events & Presentations Events Presentations Publications Stock Information Stock Quote & Chart Analyst Coverage Corporate Governance Governance Highlights Management Team Board of Directors Committee Composition Board Diversity Matrix Financials Quarterly Results Investor Resources FAQs Contact IR Email Alerts RSS Feeds Synlogic Announces Pricing of Public Offering of Common Stock Read more about Synlogic Announces Pricing of Public Offering of Common Stock Synlogic Announces Proposed Public Offering of Common Stock Read more about Synlogic Announces Proposed Public Offering of Common Stock Synlogic Announces Positive Phase 2 Data Demonstrating Reduction in Plasma Phenylalanine Levels in Patients with Phenylketonuria Read more about Synlogic Announces Positive Phase 2 Data Demonstrating Reduction in Plasma Phenylalanine Levels in Patients with Phenylketonuria Synlogic Presents Data on SYNB8802 for Enteric Hyperoxaluria at American Urological Association (AUA) Annual Meeting Read more about Synlogic Presents Data on SYNB8802 for Enteric Hyperoxaluria at American Urological Association (AUA) Annual Meeting Synlogic Presents at Global PKU Patient Meeting Read more about Synlogic Presents at Global PKU Patient Meeting Synlogic Reports Second Quarter Financial Results and Provides Business Update Read more about Synlogic Reports Second Quarter Financial Results and Provides Business Update Synlogic Announces Second Quarter 2021 Conference Call & Participation in Upcoming Banking Conference Read more about Synlogic Announces Second Quarter 2021 Conference Call & Participation in Upcoming Banking Conference Synlogic Publishes Papers in Nature Journals Demonstrating Proof-of-Mechanism and Potential of Synthetic Biotic Platform for the Treatment of Phenylketonuria (PKU) Read more about Synlogic Publishes Papers in Nature Journals Demonstrating Proof-of-Mechanism and Potential of Synthetic Biotic Platform for the Treatment of Phenylketonuria (PKU) Keay Nakae Keay Nakae Chardan knakae@chardan.com Synlogic Announces Initiation of Phase 1 Study of SYNB1934, a Next-Generation Strain for the Treatment of Phenylketonuria (PKU) Read more about Synlogic Announces Initiation of Phase 1 Study of SYNB1934, a Next-Generation Strain for the Treatment of Phenylketonuria (PKU) Pagination First page « First Previous page ‹ Previous … Page 4 Page 5 Page 6 Page 7 Current page 8 Page 9 Page 10 Page 11 Page 12 … Next page Next › Last page Last » Subscribe to Investor Resources Contact IR Investor FAQs RSS Feeds Investor Email Alerts Email
Synlogic Announces Pricing of Public Offering of Common Stock Read more about Synlogic Announces Pricing of Public Offering of Common Stock
Synlogic Announces Proposed Public Offering of Common Stock Read more about Synlogic Announces Proposed Public Offering of Common Stock
Synlogic Announces Positive Phase 2 Data Demonstrating Reduction in Plasma Phenylalanine Levels in Patients with Phenylketonuria Read more about Synlogic Announces Positive Phase 2 Data Demonstrating Reduction in Plasma Phenylalanine Levels in Patients with Phenylketonuria
Synlogic Presents Data on SYNB8802 for Enteric Hyperoxaluria at American Urological Association (AUA) Annual Meeting Read more about Synlogic Presents Data on SYNB8802 for Enteric Hyperoxaluria at American Urological Association (AUA) Annual Meeting
Synlogic Presents at Global PKU Patient Meeting Read more about Synlogic Presents at Global PKU Patient Meeting
Synlogic Reports Second Quarter Financial Results and Provides Business Update Read more about Synlogic Reports Second Quarter Financial Results and Provides Business Update
Synlogic Announces Second Quarter 2021 Conference Call & Participation in Upcoming Banking Conference Read more about Synlogic Announces Second Quarter 2021 Conference Call & Participation in Upcoming Banking Conference
Synlogic Publishes Papers in Nature Journals Demonstrating Proof-of-Mechanism and Potential of Synthetic Biotic Platform for the Treatment of Phenylketonuria (PKU) Read more about Synlogic Publishes Papers in Nature Journals Demonstrating Proof-of-Mechanism and Potential of Synthetic Biotic Platform for the Treatment of Phenylketonuria (PKU)
Synlogic Announces Initiation of Phase 1 Study of SYNB1934, a Next-Generation Strain for the Treatment of Phenylketonuria (PKU) Read more about Synlogic Announces Initiation of Phase 1 Study of SYNB1934, a Next-Generation Strain for the Treatment of Phenylketonuria (PKU)